Analyst: US vaccine order secures future cash flow for Bavarian
BARDA has utilized a contract option concerning freeze-dried smallpox vaccines developed by Bavarian, something Sydbank analyst Søren Løntoft Hansen sees as a positive signal for the biotech firm.
by marketwire, translated by catherine brett
Bavarian Nordic has secured million-dollar incomes for the next few years, as the US Biomedical Advanced Research and Development Authority (BARDA) has utilized its contracted option on Bavarian’s freeze-dried smallpox vaccine, Jynneos.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
EU to terminate vaccine agreement with Valneva
For subscribers
